Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575653 | 0.84 | MAPT (0.34) | MAPTMAPK1POLBSMN1; SMN2PPARG | |
| SCHEMBL1405820 | 0.79 | CYP1A2 (0.38) | MAPTPOLBPPARGPPARACYP1A2 | |
| SCHEMBL1405873 | 0.79 | CYP1A2 (0.38) | MAPTPOLBPPARGPPARACYP1A2 | |
| SCHEMBL4599750 | 0.79 | CYP1A2 (0.38) | MAPTPOLBPPARGPPARACYP1A2 | |
| SCHEMBL30510259 | 0.79 | CYP1A2 (0.38) | MAPTPOLBPPARGPPARACYP1A2 | |
| SCHEMBL1491452 | 0.78 | CYP1A2 (0.34) | POLBSMN1; SMN2CYP1A2TSHR | |
| SCHEMBL25177898 | 0.77 | CYP1A2 (0.37) | MAPTPOLBPPARGPPARACYP1A2 | |
| SCHEMBL14648233 | 0.76 | CYP1A2 (0.36) | MAPK1POLBPPARGPPARACYP1A2 | |
| SCHEMBL30510342 | 0.76 | CYP1A2 (0.36) | MAPK1POLBPPARGPPARACYP1A2 | |
| SCHEMBL8812896 | 0.76 | CYP1A2 (0.38) | MAPTMAPK1POLBPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194524-A1 | Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof | JERINI AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1703912-A1 | COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF | Jerini AG (DE) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005063259-A1 | COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF | JERINI AG (DE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194524-A1 | Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof | CCNB1, CCNB2, CCNA1 | MAPT 1983/4885MAPK1 219/4885POLB 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.